Previous Close | 2.4200 |
Open | 2.5100 |
Bid | 2.2900 x 29200 |
Ask | 2.3500 x 27000 |
Day's Range | 2.1700 - 2.5960 |
52 Week Range | 1.4700 - 17.4200 |
Volume | |
Avg. Volume | 6,005,585 |
Market Cap | 819.916M |
Beta (5Y Monthly) | 1.57 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.5060 |
Earnings Date | Feb 28, 2022 - Mar 04, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced that management is participating in fireside chats at the following investor conferences this week:
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform, today announced that management will participate in fireside chats at the following upcoming investor conferences.
Not long ago, Amyris and Gingko Bioworks were stock-market darlings, but the rout in tech stocks this year has been especially tough on these two. Shares of this synthetic biology start-up shot higher following its stock-market debut last year. The good times didn't last long, though, and now Gingko Bioworks stock is down more than 80% from its all-time high.